Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Non Operating Income (2019 - 2022)

Goldenwell Biotech (GWLL) has disclosed Non Operating Income for 3 consecutive years, with $1.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Non Operating Income fell 99.62% year-over-year to $1.0, compared with a TTM value of $1.0 through Mar 2023, down 99.94%, and an annual FY2021 reading of $1286.0, up 2822.73% over the prior year.
  • Non Operating Income was $1.0 for Q2 2022 at Goldenwell Biotech, down from $7.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1028.0 in Q4 2021 and bottomed at $1.0 in Q2 2022.
  • Average Non Operating Income over 3 years is $292.75, with a median of $143.5 recorded in 2020.
  • The sharpest move saw Non Operating Income soared 5060.0% in 2021, then crashed 99.62% in 2022.
  • Year by year, Non Operating Income stood at $5.0 in 2020, then surged by 20460.0% to $1028.0 in 2021, then crashed by 99.9% to $1.0 in 2022.
  • Business Quant data shows Non Operating Income for GWLL at $1.0 in Q2 2022, $7.0 in Q1 2022, and $1028.0 in Q4 2021.